Chemical: Drug
dapsone
PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.
Annotated Labels
- Annotation of FDA Label for dapsone and G6PD
- Annotation of PMDA Label for dapsone and G6PD
- Annotation of HCSC Label for dapsone and G6PD
1. Annotation of FDA Label for dapsone and G6PD
Summary
The FDA-approved label for dapsone gel provides a precautionary warning that G6PD deficient individuals may be at an increased risk of hemolytic adverse reactions, as oral dapsone treatment is associated with dose-related hemolysis and hemolytic anemia in these individuals. This enzyme deficiency is due to underlying genetic variants in the G6PD gene and can be tested for by enzyme activity or genetic tests.
There's more of this label. Read more.
2. Annotation of PMDA Label for dapsone and G6PD
Summary
The PMDA package insert for dapsone (PROTOGEN) states that hemolysis may occur in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
There's more of this label. Read more.
3. Annotation of HCSC Label for dapsone and G6PD
Summary
The product monograph for dapsone (ACZONE) notes that oral dapsone treatment can result in hemolysis and hemolytic anemia, particularly in patients who are glucose-6-phosphate dehydrogenase (G6PD)-deficient. However, for this topical formulation of the drug, a study showed no clinically relevant cases of hemolysis or anemia in G6PD-deficient individuals.
There's more of this label. Read more.
Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below.
To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.
Clinical Annotation for rs1050828 (G6PD), chlorproguanil, dapsone and Malaria (level 1B Toxicity/ADR)
To see the rest of this clinical annotation please register or sign in.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.
Links in the "Gene" column lead to PharmGKB Gene Pages.
List of all variant annotations for dapsone
| Gene ? |
Variant?
(147) |
Alternate Names ? | Chemicals ? |
Alleles
?
(+ chr strand) |
Function ? |
Amino Acid?
Translation |
|
|---|---|---|---|---|---|---|---|
VA
|
G6PD | A- 202A_376G | N/A | N/A | N/A | ||
|
CA
VA
|
HLA-B | *13:01:01 | N/A | N/A | N/A | ||
| rs1050828 | NC_000023.10:g.153764217C>T, NC_000023.11:g.154536002C>T, NG_009015.2:g.16571G>A, NM_000402.4:c.292G>A, NM_001042351.2:c.202G>A, NP_000393.4:p.Val98Met, NP_001035810.1:p.Val68Met, NW_003871103.3:g.1969981C>T, XM_005274657.1:c.292G>A, XM_005274657.2:c.292G>A, XM_005274658.1:c.202G>A, XM_005274658.2:c.202G>A, XM_005277833.1:c.292G>A, XM_005277834.1:c.202G>A, XM_011531132.1:c.292G>A, XP_005274714.1:p.Val98Met, XP_005274715.1:p.Val68Met, XP_005277890.1:p.Val98Met, XP_005277891.1:p.Val68Met, XP_011529434.1:p.Val98Met, rs1894404, rs2230034, rs3191188 |
C > T
|
SNP |
V98M
|
|||
| rs776746 | NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770 |
C > T
|
SNP |
Overview
- Acedapsone
- DADPS
- DDS
- DSS
- Dapson
- Dapsonum
- Dds, Diaphenylsulfone
- Dds, Pharmaceutical
- Diamino-diphenyl sulphone
- Diaminodifenilsulfona
- Diaminodiphenyl Sulfone
- Diaphenylsulfon
- Diaphenylsulfone
- Diaphenylsulphon
- Diaphenylsulphone
- Diphenasone
- Metabolite C
- N, N'-Diphenyl Sulfondiamide
- P, P'-Sulfonyldianiline
- P,P'-Diaminodiphenyl Sulfone
- P,P-Diaminodiphenyl Sulphone
- P,P-Sulfonylbisbenzamine
- P,P-Sulfonylbisbenzenamine
- P,P-Sulphonylbisbenzamine
- P,P-Sulphonylbisbenzenamine
- P,P-Sulphonyldianiline
- P-Aminophenyl Sulfone
- Sulfonyldianiline
- Sulphadione
- Sulphonyldianiline
- dapsone
- Araldite Ht
- Avlosulfon
- Avlosulfone
- Avlosulphone
- Croysulfone
- Croysulphone
- Dimitone
- Diphone
- Dubronax
- Dumitone
- Eporal
- ICI
- Normet
- Novophone
- Recolip
- Sulfadione
- Sulfanona-Mae
- Sulfon-Mere
- Sulfona
- Sulfona-Mae
- Sulfone Ucb
- Sulphon-Mere
- Sumicure S
- Tarimyl
- Udolac
PharmGKB Accession Id
PA449211
Type(s):
Drug
Description
Source: Drug Bank
Indication
Source: Drug Bank
Other Vocabularies
- ATC: Drugs for treatment of lepra (J04BA)
- UMLS: Dapsone (C0010980)
- RxNorm: Dapsone (3108)
- NDFRT: DAPSONE (N0000147467)
Information pulled from DrugBank has not been reviewed by PharmGKB.
Pharmacology, Interactions, and Contraindications
Mechanism of Action
Source: Drug Bank
Pharmacology
Source: Drug Bank
Absorption, Distribution, Metabolism, Elimination & Toxicity
Toxicity
Source: Drug Bank
Chemical Properties
SMILES
NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
Source: Drug Bank
InChI String
InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
Source: Drug Bank
Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.
Curated Information ?
Drug Targets
| Gene | Description |
|---|---|
| DHFR | (source: Drug Bank ) |
Curated Information ?
Relationships from National Drug File - Reference Terminology (NDF-RT)
May Treat
- dapsone may treat AIDS-Related Opportunistic Infections
- dapsone may treat Dermatitis Herpetiformis
- dapsone may treat Leprosy
- dapsone may treat Leprosy, Lepromatous
- dapsone may treat Polychondritis, Relapsing
May Prevent
- dapsone may prevent Malaria
- dapsone may prevent Toxoplasmosis
Contraindicated With
- dapsone contraindicated with Drug Hypersensitivity
Publications related to dapsone: 30
LinkOuts
- Web Resource:
- Wikipedia
- National Drug Code Directory:
- 0469-5005-03
- DrugBank:
- DB00250
- ChEBI:
- 4325
- Drugs Product Database (DPD):
- 2041510
- BindingDB:
- 50029764
- ChemSpider:
- 2849
- Therapeutic Targets Database:
- DAP000637
- FDA Drug Label at DailyMed:
- aa249ecd-afd3-4800-b196-d4f7b8c8fc6e
Clinical Trials
These are trials that mention dapsone and are related to either pharmacogenetics or pharmacogenomics.
NURSA Datasets
No NURSA datasets available.